EW's Q1 Earnings Beat, Revenues Match, '26 View Up, Stock Climbs

Edwards Lifesciences beats on Q1 earnings, matches revenue estimates, lifts 2026 outlook as TAVR and TMTT growth accelerates; shares rise on stronger guidance and margin expansion.